Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
36.5M
-
Shares change
-
+1.66M
-
Total reported value, excl. options
-
$886M
-
Value change
-
+$12.9M
-
Put/Call ratio
-
0.75
-
Number of buys
-
68
-
Number of sells
-
-50
-
Price
-
$24.26
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q1 2022
149 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q1 2022.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.5M shares
of 70.9M outstanding shares and own 51.52% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (4.53M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.38M shares), BlackRock Inc. (3.14M shares), STATE STREET CORP (2.23M shares), PERCEPTIVE ADVISORS LLC (2.08M shares), VANGUARD GROUP INC (2.02M shares), ArrowMark Colorado Holdings LLC (1.91M shares), Bain Capital Life Sciences Investors, LLC (1.64M shares), WASATCH ADVISORS INC (1.54M shares), and PICTET ASSET MANAGEMENT SA (1.13M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.